References
- Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478–1484.
- Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. JCO. 2003;21:607–614.
- Santoro A, Bonadonna G, Valagussa P, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. JCO. 1987;5:27–37.
- Evens AM, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood. 2012;119:692–695.
- Martin W, Ristow K, Habermann T, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. JCO. 2005;23:7614–7620.
- Sleijfer S. Bleomycin-induced pneumonitis. Chest. 2001;120:617–624.
- Horning SJ, Adhikari A, Rizk N, et al. Effect of treatment for Hodgkin's disease on pulmonary function: results of a prospective study. J Clin Oncol. 1994;12:297–305.
- Matthews JH. Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin’s disease: possible synergy. Lancet. 1993;342:988.
- Ngeow J, Tan IB, Kanesvaran R, et al. Prognostic impact of bleomycin-induced pneumonitis on the outcome of Hodgkin's lymphoma. Ann Hematol. 2011;90:67–72.
- O'Sullivan JM, Huddart RA, Norman AR, et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003;14:91–96.
- Senan S, Paul J, Thomson N, et al. Cigarette smoking is a risk factor for bleomycin-induced pulmonary toxicity. Eur J Cancer. 1992;28A:2084.
- Fong D, Steurer M, Greil R, et al. Hodgkin lymphoma in Tyrol-a population-based study. Ann Hematol. 2009;88:449–456.
- Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin’s disease staging classification. Cancer Res. 1971;31:1860–1861.
- Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease: International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med. 1998;339:1506–1514.
- Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–655.
- Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. JCO. 1999;17:1244.
- Canellos GP, Duggan D, Johnson J, et al. How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? JCO. 2004;22:1532–1533.
- Evens AM, Cilley J, Ortiz T, et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol. 2007;137:545–552.
- Minuk LA, Monkman K, Chin-Yee IH, et al. Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study. Leuk Lymphoma. 2012;53:57–63.
- McKeage MJ, Evans BD, Atkinson C, et al. Carbon monoxide diffusing capacity is a poor predictor of clinically significant bleomycin lung. New Zealand Clinical Oncology Group. JCO. 1990;8:779–783.
- Eichenauer DA, Engert A, André M, ESMO Guidelines Working Group, et al. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25:70–75.
- Hoppe RT, Advani RH, Ai WZ, et al. NCCN Hodgkin lymphoma. J Natl Compr Canc Netw. 2011;9:1020–1058.
- Böll B, Goergen H, Behringer K, et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016;127:2189–2192.
- Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med. 2016;374:2419–2429.
- Ansell SM, Younes A, Connors JM, et al. Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study [abstract]. J Clin Oncol. 2014;32.